Zacks Research Analysts Increase Earnings Estimates for GSK

GSK PLC Sponsored ADR (NYSE:GSK) – Investment analysts at Zacks Research lifted their FY2026 EPS estimates for shares of GSK in a report issued on Tuesday, September 2nd. Zacks Research analyst Team now anticipates that the pharmaceutical company will post earnings of $4.74 per share for the year, up from their previous estimate of $4.70. The consensus estimate for GSK’s current full-year earnings is $4.14 per share. Zacks Research also issued estimates for GSK’s FY2027 earnings at $4.78 EPS.

GSK has been the topic of several other reports. Wall Street Zen upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday. Berenberg Bank reiterated a “hold” rating on shares of GSK in a research note on Tuesday, June 3rd. Six research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus price target of $37.38.

GSK Trading Up 2.0%

GSK opened at $40.41 on Friday. The stock has a market capitalization of $82.30 billion, a P/E ratio of 18.71, a P/E/G ratio of 1.71 and a beta of 0.53. GSK has a 12 month low of $31.72 and a 12 month high of $44.19. The firm’s fifty day simple moving average is $38.51 and its 200 day simple moving average is $38.33. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion for the quarter, compared to analysts’ expectations of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The firm’s revenue was up 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Twin Peaks Wealth Advisors LLC acquired a new position in shares of GSK during the 2nd quarter worth about $25,000. HHM Wealth Advisors LLC grew its stake in GSK by 222.2% in the 1st quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 460 shares during the last quarter. Costello Asset Management INC bought a new position in GSK in the 1st quarter valued at about $31,000. SOA Wealth Advisors LLC. lifted its position in GSK by 252.1% during the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 605 shares during the last quarter. Finally, Richardson Financial Services Inc. lifted its position in GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company’s stock worth $33,000 after acquiring an additional 472 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Stockholders of record on Friday, August 15th will be paid a dividend of $0.4206 per share. The ex-dividend date is Friday, August 15th. This represents a $1.68 annualized dividend and a dividend yield of 4.2%. GSK’s payout ratio is currently 77.78%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.